Skip to content

Dopaminergic and noradrenergic dynamics after acute stress

Dopaminergic and noradrenergic dynamics after acute stress - DANDYN

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON51949
Enrollment
132
Registered
2022-03-08
Start date
2022-06-22
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety disorders Stress-related disorders

Interventions

This study will investigate four groups. The first group receives the control procedure, while groups 2,3, and four undergo the stress procedure. Group 1 and 2 additionally receive two placebos. The

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 40 Right handed BMI between 18.5 and 30 Normal or corrected to normal vision Speaking and understanding of the English language

Exclusion criteria

Exclusion criteria: Incompatibility with the MRI scanner History of brain surgery Possible pregnancy Breastfeeding Color blindness Any relevant current or past psychiatric or psychotic disorder, including suicidality First degree family member with schizophrenia, bipolar disorder, or major depressive disorder Neurological disorder Endocrine disorder Endocrine treatment Glaucoma or increased risk for glaucoma Melanoma or undiagnosed skin lesion Any other clinically significant hepatic, metabolic, obstructive respiratory, renal, cerebrovascular, cardiovascular, oncological, ocular or pulmonary disease/disorders Raynaud*s syndrome Hypersensitivity to Haloperidol or Propranolol Hypertension (i.e. diastolic blood pressure >95 mmHg at rest, or systolic blood pressure >180 mmHg at rest) Hypotension (i.e. diastolic blood pressure

Design outcomes

Primary

MeasureTime frame
The main study parameters are the comparison of oddball performance and performance in the cue-guided versus memory-guided attention task, between the stress and placebo group, the stress and haloperidol group, and the stress and propranolol group.

Secondary

MeasureTime frame
In this study, three secondary outcome parameters are measured. First, the difference in vigilance and striatal-dependent cognition between the group receiving Propranolol and the group receiving Haloperidol is investigated. Second, the difference in neural activity between the different groups is assessed during the oddball and visual search task. Third, the difference in behavioral measures and neural activity in the different groups is measured during a motivation task, a working memory task, and an emotion task.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)